Clinical Pharmacology of Proton Pump Inhibitors (original) (raw)

• Sonnenberg A, El-Serag HB. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med 1999 Mar–Jun; 72: 81–92
  PubMed CAS Google Scholar
• Jones R, Bytzer P. Review article: acid suppression in the management of gastro-oesophageal reflux disease: an appraisal of treatment options in primary care. Aliment Pharmacol Ther 2001 Jun; 15: 765–72
  Article PubMed CAS Google Scholar
• Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9 Suppl. 1: 9–14
  PubMed Google Scholar
• DeVault KR. Gastroesophageal reflux disease: extraesophageal manifestations and therapy. Semin Gastrointest Dis 2001 Jan; 12: 46–51
  PubMed CAS Google Scholar
• Salas M, Ward A, Caro J. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers?: a meta-analysis of randomized clinical trials. BMC Gastroenterol 2002 Jul 15; 2: 17–23
  Article PubMed Google Scholar
• Barrison AF, Jarboe LA, Weinberg BM, et al. Patterns of proton pump inhibitor use in clinical practice. Am J Med 2001 Oct 15; 111: 469–73
  Article PubMed CAS Google Scholar
• Robinson M. Dyspepsia: challenges in diagnosis and selection of treatment. Clin Ther 2001 Aug; 23: 1130–44
  Article PubMed CAS Google Scholar
• Sachs G. Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol 2001 May; 13 Suppl. 1: S35–41
  PubMed Google Scholar
• Besancon M, Simon A, Sachs G, et al. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997 Sep 5; 272: 22438–46
  Article PubMed CAS Google Scholar
• Kromer W. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. Scand J Gastroenterol Suppl 2001; 234: 3–9
  Article PubMed Google Scholar
• Kromer W, Kruger U, Huber R, et al. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 1998 Feb; 56: 57–70
  Article PubMed CAS Google Scholar
• Pantoflickova D, Dorta G, Ravic M, et al. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003 Jun 15; 17: 1507–14
  Article PubMed CAS Google Scholar
• Williams MP, Sercombe J, Hamilton MI, et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole vs omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998 Nov; 12: 1079–89
  Article PubMed CAS Google Scholar
• Gardner JD, Sloan S, Barth JA. Onset, duration, and magnitude of gastric antisecretory effects of rabeprazole and omeprazole [abstract no. 125]. Am J Gastroenterol 1999 Oct; 94 Suppl.: 2608
  Google Scholar
• Huang JQ, Goldwater DR, Thomson AB, et al. Acid suppression in healthy subjects following lansoprazole or pantopra-zole. Aliment Pharmacol Ther 2002 Mar; 16: 425–33
  Article PubMed CAS Google Scholar
• Geus WP, Mathot RA, Mulder PG, et al. Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects. Aliment Pharmacol Ther 2000 Aug; 14: 1057–64
  Article PubMed CAS Google Scholar
• Ehrlich A, Lucker PW, Wiedemann A, et al. Comparison of the pharmacodynamics and pharmacokinetics of pantoprazole (40 mg) as compared to omeprazole MUPS (20 mg) after repeated oral dose administration. Methods Find Exp Clin Pharmacol 1999 Jan–Feb; 21: 47–51
  Article PubMed CAS Google Scholar
• Warrington S, Baisley K, Boyce M, et al. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment Pharmacol Ther 2002 Jul; 16: 1301–7
  Article PubMed CAS Google Scholar
• Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000 Jul; 14: 861–7
  Article PubMed CAS Google Scholar
• Wilder-Smith C, Claar-Nilsson C, Hasselgren G, et al. Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD [abstract no. 137]. Am J Gastroenterol 2001 Sep; 96 Suppl.: S45
  Article Google Scholar
• Baisley KJ, Warrington SJ, Tejura B, et al. Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers [abstract no. 229]. Gut 2002 Oct; 50 Suppl. II: A63
  Google Scholar
• Scott LJ, Dunn CJ, Mallarkey G, et al. Esomeprazole: a review of its use in management of acid-related disorders. Drugs 2002 Oct; 62: 1503–38
  Article PubMed CAS Google Scholar
• Prakash A, Faulds D. Rabeprazole. Drugs 1998 Feb; 55: 261–7
  Article PubMed CAS Google Scholar
• Landes BD, Petite JP, Fluovat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995 Jun; 28: 458–70
  Article PubMed CAS Google Scholar
• Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996 May; 34: 185–94
  PubMed CAS Google Scholar
• Barone J, Horn JR. Comparative pharmacology of proton pump inhibitors. Manag Care 2001; 10 Suppl.: 11–6
  PubMed CAS Google Scholar
• Touw DJ. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes. Drug Metabol Drug Interact 1997; 14: 55–82
  PubMed CAS Google Scholar
• Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors: emphasis on rabeprazole. Aliment Pharmacol Ther 1999 Aug; 13 Suppl. 3: 27–36
  Article PubMed CAS Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 411–26
  Article PubMed CAS Google Scholar
• Andersson T, Röhss K, Bredberg E, et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the s-isomer of omeprazole. Aliment Pharmacol Ther 2001 Oct; 15: 1563–9
  Article PubMed CAS Google Scholar
• Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001 Oct; 52: 349–55
  Article PubMed CAS Google Scholar
• Sakai T, Aoyama N, Kita T, et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001 Jun; 18: 721–7
  Article PubMed CAS Google Scholar
• Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001 Dec; 15: 1929–37
  Article PubMed CAS Google Scholar
• Furuta T, Kyoichi O, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999 May; 65: 552–61
  Article PubMed CAS Google Scholar
• Furuta T, Shirai N, Xiao F, et al. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C 19. Clin Pharmacol Ther 2001 Nov; 70: 484–92
  Article PubMed CAS Google Scholar
• Horai Y, Kimura M, Furuie H, et al. Pharmacodynamic effect and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001 Jun; 15: 793–803
  Article PubMed CAS Google Scholar
• Röhss K, Hasselgren G, Hedenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002 May; 47: 954–8
  Article PubMed Google Scholar
• Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998 Nov; 35: 361–90
  Article PubMed CAS Google Scholar
• Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999 Aug; 13 Suppl. 3: 18–26
  Article PubMed CAS Google Scholar
• Hansten P, Horn J. The top 100 drug interactions: a guide to patient management. Edmonds (WA): H&H Publications, 2003: 30, 121–34
  Google Scholar
• Bottiger Y, Tybring G, Gotharson E. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1997 Oct; 62: 384–91
  Article PubMed CAS Google Scholar
• Christensen M, Tybring G, Mihara K, et al. Low daily 10 mg and 20 mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 2002 Mar; 71: 141–52
  Article PubMed CAS Google Scholar
• Schouler L, Dumas F, Couzigou P, et al. Omeprazole-cyclosporin interaction [letter]. Am J Gastroenterol 1991 Aug; 86:1097
  PubMed CAS Google Scholar
• Marti-Masso JF, Lopez D, Munian A, et al. Ataxia following gastric bleeding due to omeprazole-benzodiazepine interaction [letter]. Ann Pharmacother 1992 Mar; 26: 429–30
  PubMed CAS Google Scholar
• Ahmad S. Omeprazole-warfarin interaction [letter]. South Med J 1991 May; 84: 674–5
  PubMed CAS Google Scholar
• AstraZeneca LP. Prilosec (omeprazole). United States prescribing information. Wilmington (DE): AstraZeneca LP, 2003
  Google Scholar
• Ushiama H, Echizen H, Nachi S, et al. Dose-dependent inhibition of CYP3A4 activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6β-hydroxycortisol. Clin Pharmacol Ther 2002 Jul; 72: 33–43
  Article PubMed CAS Google Scholar
• Homma M, Itagaki F, Yuzawa K, et al. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation 2002 Jan 27; 73: 303–4
  Article PubMed Google Scholar
• Tröger U, Stötzel B, Martens-Lobenhoffer J, et al. Drug points: severe myalgia from an interaction between treatments with pantoprazole and methotrexate. BMJ 2002 Jun 22; 324: 1497
  Article PubMed Google Scholar
• Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther 1995 Aug; 58: 155–64
  Article PubMed CAS Google Scholar
• Andersson T, Hassan-Alin M, Hasselgren G, et al. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 523–37
  Article PubMed CAS Google Scholar
• Tybring G, Bottiger Y, Widen J, et al. Enantioselective hydroxylation of omeprazole catalyzed by CYP 2C19 in Swedish white subjects. Clin Pharmacol Ther 1997 Aug; 62: 129–37
  Article PubMed CAS Google Scholar
• Belpaire FM, Bogaert MG. Cytochrome P450: genetic polymorphism and drug interactions. Acta Clin Belg 1996; 51: 254–60
  PubMed CAS Google Scholar
• Yu KS, Yim DS, Cho JY, et al. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C 19. Clin Pharmacol Ther 2001 Apr; 69: 266–73
  Article PubMed CAS Google Scholar
• Furuta T, Ohashi K, Kobayashi K, et al. Effects of clarithroymycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 1999 Sep; 66: 265–74
  Article PubMed CAS Google Scholar
• Lind T, Rydberg L, Kyleback A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000 Jul; 14: 861–7
  Article PubMed CAS Google Scholar
• Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001 Jul; 23: 998–1017
  Article PubMed CAS Google Scholar
• Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001 Mar; 96: 656–65
  Article PubMed CAS Google Scholar
• Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000 Oct; 14: 1249–58
  Article CAS Google Scholar
• AstraZeneca LP. Nexium (esomeprazole). United States prescribing information. Wilmington (DE): AstraZeneca LP, 2003
  Google Scholar
• Howden C, Ballard D, Robieson W. Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis. Clin Drug Invest 2002; 22: 99–109
  Article CAS Google Scholar
• Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002 Mar; 97: 575–83
  Article PubMed CAS Google Scholar
• Cohen H. Peptic ulcer and Helicobacter pylori. Gastroenterol Clin North Am 2000 Dec; 29: 775–89
  Article PubMed CAS Google Scholar
• Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998 Sep; 56: 307–35
  Article PubMed CAS Google Scholar
• Van Oijen AH, Verbeek AL, Jansen JB, et al. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. Aliment Pharmacol Ther 2000 Aug; 14: 991–9
  Article PubMed Google Scholar
• Yeomans ND. Management of peptic ulcer disease not related to Helicobacter. J Gastroenterol Hepatol 2002 Apr; 17: 488–94
  Article PubMed Google Scholar
• Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002 Jan 28; 162: 169–75
  Article PubMed CAS Google Scholar
• Agrawal NM, Campbell DR, Safdi MA, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000 May 22; 160: 1455–61
  Article PubMed CAS Google Scholar
• Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term lowdose aspirin use. N Engl J Med 2002 Jun 27; 346: 2033–8
  Article PubMed CAS Google Scholar
• Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclo-fenac and omeprazole in reducing the risk of recurrent bleeding in patients with arthritis. N Engl J Med 2002 Dec 26; 347: 2104–10
  Article PubMed CAS Google Scholar
• Bour B, Pariente EA, Hamelin B, et al. Orally administered omeprazole versus injection therapy in the prevention of rebleeding from peptic ulcer with visible vessel: a multicenter randomized study. Gastroenterol Clin Biol 1993; 17: 329–33
  PubMed CAS Google Scholar
• Mohamed SA, al Karawi MA. Omeprazole versus histamine H2 receptor antagonists in the treatment of acute upper nonvariceal bleeding. Hepatogastroenterology 1996 Jul–Aug; 43: 863–5
  PubMed CAS Google Scholar
• Barnett JL, Robinson M. Optimizing acid-suppression therapy. Manag Care 2001 Oct; 10 Suppl. 10: 17–21
  PubMed CAS Google Scholar
• Smith JL, Opedun AR, Larkai E, et al. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology 1989 Mar; 96: 683–9
  PubMed CAS Google Scholar
• Achem SR. Endoscopy-negative gastroesophageal reflux disease: the hypersensitive esophagus. Gastroenterol Clin North Am 1999 Dec; 28: 893–904
  Article PubMed CAS Google Scholar
• Bate CM, Griffin SM, Keeling PWN, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996 Aug; 10: 547–55
  Article PubMed CAS Google Scholar
• Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997 Oct; 32: 974–9
  Article PubMed CAS Google Scholar
• Venables TL, Newland RD, Patel AC, et al. Maintenance treatment for gastro-oesophageal reflux disease: a placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol 1997 Jul; 32: 627–32
  Article PubMed CAS Google Scholar
• Richter JE, Kovacs TO, Greski-Rose PA, et al. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 1999 Jun; 13: 795–804
  Article PubMed CAS Google Scholar
• Miner Jr P, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002 Jun; 97: 1332–9
  Article PubMed CAS Google Scholar
• DeVault KR, Castell DO, The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999 Jun; 94: 1434–42
  Article PubMed CAS Google Scholar
• El-Serag HB, Aguirre T, Kubeler M, et al. The length of newly diagnosed Barrett’s esophagus and prior use of acid suppressive therapy [abstract no. 14]. Am J Gastroenterol 2003 Sep; 98 (9 Suppl.): S5
  Article Google Scholar
• Aguirre T, El-Serag H, Davis S, et al. Proton pump inhibitors reduce the incidence of dysplasia in Barrett’s esophagus [abstract no. 66]. Am J Gastroenterol 2003 Sep; 98 (9 Suppl.): S23
  Google Scholar
• Bank S, Singh R, Indaram A, et al. Maintenance proton pump inhibitor therapy decreases the incidence of esophageal cancer and high-grade dysplasia in Barrett’s esophagus and chronic heartburn [abstract no. 88]. Am J Gastroenterol 2003 Sep; 98 (9 Suppl.): S31
  Google Scholar
• Koop H. Gastroesophageal reflux disease and Barrett’s esophagus. Endoscopy 2002 Feb; 34: 97–103
  Article PubMed CAS Google Scholar
• Fass R, Ofman JJ. Gastroesophageal reflux disease: should we adopt a new conceptual framework? Am J Gastroenterol 2002 Aug; 97: 1901–9
  PubMed Google Scholar
• Hungin AP, Rubin GP, O’Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999 Jun; 49: 451–3
  PubMed CAS Google Scholar
• Hungin AP, Rubin G, O’Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999 Jun; 49: 463–4
  PubMed CAS Google Scholar
• Barnett JL, Robinson M. Optimizing acid-suppression therapy. Manag Care 2001 Oct; 10 Suppl.: 17–21
  PubMed CAS Google Scholar
• Bardhan KD, Müller-LissnerS,Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. BMJ 1999 Feb 20; 318: 502–7
  Article PubMed CAS Google Scholar
• Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis: a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999 Jul; 13: 907–14
  Article PubMed CAS Google Scholar
• Gerson LB, Robbins AS, Garber A, et al. A cost-effectiveness analysis of prescribing strategies in the management of gastro-esophageal reflux disease. Am J Gastroenterol 2000 Feb; 95: 395–407
  Article PubMed CAS Google Scholar
• Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesopheageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001 Mar; 15: 347–54
  Article PubMed CAS Google Scholar
• Johnsson F, Moum R, Vilien O, et al. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol 2002 Jun; 37: 642–7
  Article PubMed CAS Google Scholar
• Talley NJ, Venables TL, Green JR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002 Aug; 14: 857–63
  Article PubMed CAS Google Scholar
• Byzter P, Blum AL, de Herdt D. Fast and complete control of heartburn in on-demand rabeprazole (RAB) maintenance therapy in patients with nonerosive reflux disease (NERD) [abstract no. 1596]. Gastroenterology 2003; 124 Suppl. 1: A228
  Google Scholar